Recombinant Human Fas Ligand (FasL)
| Code | Size | Price |
|---|
| LEI-F115-10ug | 10 ug | £329.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
Ambient
Storage:
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Further Information
Format:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 with no calcium, magnesium, or preservatives.
Formulation:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 with no calcium, magnesium, or preservatives.
Long Description:
Fas ligand (FasL), also known as TNFSF6, is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family and is involved in membrane mediated apoptosis. The specific receptor for FasL is Fas (CD95, Apo-1). FasL is primarily expressed on activated T cells and NK cells, while Fas is expressed on various types of cells. Ligation of Fas by FasL triggers activation of the caspase cascade. Functional impairment of the Fas/FasL system is associated with the development and progression of malignancies. Tumor cells frequently exhibit de novo expression of FasL, which plays a significant role in local tissue destruction, metastatic spread and immune escape of the tumor cells.1 The apoptosis of lymphocytes, which occurs in autoimmune diseases, is usually induced by the Fas/FasLsystem, therefore, FasL is regarded as a potential target for immunotherapy.2 One study has suggested a correlation between high levels of FasL expression in the cornea and successful corneal transplantation.3
NCBI Gene:
356
Purity:
>95% by SDS-PAGE and analyzed by silver stain.
Target:
Fas Ligand
References
1. Igney, FH. et al. (2005) Cancer Immunol. Immunother. 54:11272. Ottmar, J. et al. (2008) Cell Communication and Signaling 6:113. Stuart, P. et al. (1997) J. Clin. Investigation 99:396
Related Products
| Product Name | Product Code | Supplier | Recombinant Mouse Fas Ligand | LEI-F1037 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Mouse Fas Ligand (Clone 101624) | LEI-F1074 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse Fas Ligand (Clone 101626) | LEI-F1075 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse Fas Ligand | LEI-F1088 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse Fas Ligand - Biotin | LEI-F1099 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human Fas Ligand | LEI-F1126 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||